Ramelteon

• UNSPSC Description:

  Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

• Target Antigen:

  Melatonin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Neurological Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ramelteon.html

• Purity:

  99.87

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C(NCC[C@H]1C2=C(C=CC3=C2CCO3)CC1)CC

• Molecular Weight:

  259.349

• References & Citations:

  [1]Kato K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-310.|[2]Mayer G, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351-360. |[3]Hirai K, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005;20(1):27-37.|[4]Miyamoto M, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep. 2004;27(7):1319-1325.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  196597-26-9